Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

被引:28
|
作者
Gelhorn, Heather L. [1 ]
Bacci, Elizabeth D. [2 ]
Poon, Jiat Ling [1 ]
Boye, Kristina S. [3 ]
Suzuki, Shuichi [4 ]
Babineaux, Steven M. [3 ]
机构
[1] Evidera, Outcomes Res, Bethesda, MD USA
[2] Evidera, Seattle, WA USA
[3] Eli Lilly & Co, Global Patient Outcomes & Real World Evidence, Indianapolis, IN 46285 USA
[4] Eli Lilly Japan, Med Dev Unit Japan, Kobe, Hyogo, Japan
来源
PATIENT PREFERENCE AND ADHERENCE | 2016年 / 10卷
关键词
discrete choice experiment; patient's preference; type; 2; diabetes; GLP-1 receptor agonists; willingness to inject; DISCRETE-CHOICE EXPERIMENT; LIRAGLUTIDE; MELLITUS;
D O I
10.2147/PPA.S109289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients' preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. Methods: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: "dosing frequency", "hemoglobin A1c change", "weight change", "type of delivery system", "frequency of nausea", and "frequency of hypoglycemia". Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. Results: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation = 10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation = 5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). Conclusion: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients' preferences that may be informative for patient-clinician treatment discussions.
引用
收藏
页码:1337 / 1348
页数:12
相关论文
共 50 条
  • [21] Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Harris, Kira B.
    McCarty, Delilah J.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 3 - 18
  • [22] Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden
    Svensson, Ann-Marie
    Toll, Anders
    Lebrec, Jeremie
    Miftaraj, Mervete
    Franzen, Stefan
    Eliasson, Bjoern
    DIABETES OBESITY & METABOLISM, 2021, 23 (03) : 720 - 729
  • [23] Effects of Glucagon-Like Peptide-1 Receptor Agonists on beta-Cell Function in Patients with Type 2 Diabetes
    Grandy, Susan
    Shaunik, Alka
    Hardy, Elise
    JOURNAL OF DIABETES & METABOLISM, 2016, 7 (01)
  • [24] Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world
    Franch-Nadal, Josep
    Granado-Casas, Minerva
    Mata-Cases, Manel
    Ortega, Emilio
    Vlacho, Bogdan
    Mauricio, Didac
    PRIMARY CARE DIABETES, 2022, 16 (06) : 810 - 817
  • [25] Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review
    Joshi, Nandan
    Baloch, Kanwal Mir
    Rukh, Shah
    Khan, Abdul Moiz
    Muskan, Fnu
    Kumari, Verkha
    Khan, Hasher
    Zeeshan, Mohd
    Azam, Ghufran
    Khalid, Saif
    Anwar, Insa Binte
    Ahmed, Iqra Furqan
    Nishat, Syeed Mahmud
    Gandhi, Fenil
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (12): : 7255 - 7264
  • [26] Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella, Raffaella
    Pechtner, Valeria
    Corcos, Antonella
    Consoli, Agostino
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
  • [27] Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
    Tan, Xinrui
    Pan, Xiongfeng
    Wu, Xiaochuan
    Zheng, Songjia
    Chen, Yuyao
    Liu, Donghai
    Zhang, Xingxing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [28] Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
    Berlie, Helen
    Hurren, Kathryn M.
    Pinelli, Nicole R.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 165 - 174
  • [29] Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease A Review
    Honigberg, Michael C.
    Chang, Lee-Shing
    McGuire, Darren K.
    Plutzky, Jorge
    Aroda, Vanita R.
    Vaduganathan, Muthiah
    JAMA CARDIOLOGY, 2020, 5 (10) : 1182 - 1190
  • [30] Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
    Sun, Feng
    Wu, Shanshan
    Wang, Jing
    Guo, Shuxia
    Chai, Sanbao
    Yang, Zhirong
    Li, Lishi
    Zhang, Yuan
    Ji, Linong
    Zhan, Siyan
    CLINICAL THERAPEUTICS, 2015, 37 (01) : 225 - 241